keyword
MENU ▼
Read by QxMD icon Read
search

Metastasectomy

keyword
https://www.readbyqxmd.com/read/28637066/-surgery-for-pulmonary-metastases-in-patients-with-advanced-soft-tissue-and-osteosarcomas
#1
Sascha Macherey, Khosro Hekmat, Kourosh Zarghooni, Fabian Doerr, Matthias Heldwein, Thorsten Wahlers
Background Advanced soft tissue or osteosarcoma is often associated with lung metastases. Curative pulmonary metastasectomy is appropriate for patients with successfully resected primary cancer who show no evidence of extrapulmonary metastases, with proven functional operability and completely resectable metastases. Material and Methods Systematic literature research and qualitative analysis of studies on patients undergoing lung metastasectomy after resection of primary sarcoma published since 01.01.2010. We assessed operative findings, survival data and prognostic factors...
June 21, 2017: Zeitschrift Für Orthopädie und Unfallchirurgie
https://www.readbyqxmd.com/read/28634014/chemotherapy-for-resected-colorectal-cancer-pulmonary-metastases-utilization-and-outcomes-in-routine-clinical-practice
#2
S Karim, S Nanji, K Brennan, C S Pramesh, C M Booth
BACKGROUND: The role of chemotherapy in the setting of resected colorectal cancer pulmonary metastases (CRCPM) is not well defined. Here we describe utilization of peri-operative chemotherapy and outcomes among patients with resected CRCPM in the general population. METHODS: All cases of CRCPM who underwent resection from 2002 to 2009 were identified using the Ontario Cancer Registry (OCR). Electronic treatment records identified peri-operative chemotherapy delivered within 16 weeks before or after pulmonary metastasectomy (PM)...
June 1, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28627996/metastasectomy-for-colorectal-cancer-are-there-clothes-on-the-emperor
#3
Tom Treasure
No abstract text is available yet for this article.
June 2017: Journal of the Royal Society of Medicine
https://www.readbyqxmd.com/read/28625333/liver-metastases-from-gastric-carcinoma-a-case-report-and-review-of-the-literature
#4
Beata Polkowska-Pruszyńska, Karol Rawicz-Pruszyński, Bogumiła Ciseł, Robert Sitarz, Grażyna Polkowska, Witold Krupski, Wojciech P Polkowski
Gastric carcinoma (GC) is the fifth most common malignancy worldwide but the third leading cause of cancer death, and surgery remains the only curative treatment option. Prognosis of patients with liver metastases from gastric carcinoma (LMGC) is poor, and the optimal treatment of metastatic gastric cancer remains a matter of debate. In 2002, a 53-year-old male patient with GC and synchronous oligometastatic lesion in liver VIII segment underwent a total gastrectomy combined with metastasectomy. The pathologic diagnosis was stage IV gastric adenocarcinoma (pT3N2M1), which was treated with adjuvant chemotherapy (cisplatin, epirubicin, leucovorin, and 5-fluorouracil)...
May 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/28620578/surgical-management-of-advanced-and-metastatic-renal-cell-carcinoma-a-multidisciplinary-approach
#5
REVIEW
Brian M Shinder, Kevin Rhee, Douglas Farrell, Nicholas J Farber, Mark N Stein, Thomas L Jang, Eric A Singer
The past decade has seen a rapid proliferation in the number and types of systemic therapies available for renal cell carcinoma. However, surgery remains an integral component of the therapeutic armamentarium for advanced and metastatic kidney cancer. Cytoreductive surgery followed by adjuvant cytokine-based immunotherapy (predominantly high-dose interleukin 2) has largely given way to systemic-targeted therapies. Metastasectomy also has a role in carefully selected patients. Additionally, neoadjuvant systemic therapy may increase the feasibility of resecting the primary tumor, which may be beneficial for patients with locally advanced or metastatic disease...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28612618/durable-complete-response-of-colorectal-cancer-metastasis-after-biochemotherapy
#6
M Honzirkova, L Lipská, P Kohout, J Ferda, O Bělohlávek, T Büchler
BACKGROUND: Resection of the metastatic site is indicated but not always possible in patients with metastatic colorectal cancer (mCRC) who achieve a partial or complete response (CR) to induction systemic treatment. CR after systemic treatment alone is uncommon, and even patients with radiologic CR after induction chemotherapy harbour persistent macroscopic or microscopic residual disease in more than 80% of cases. Occasionally, some metastatic lesions disappear radiologically but others persist after induction systemic treatment...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28607592/the-role-of-adjuvant-chemotherapy-for-colorectal-liver-metastasectomy-after-pre-operative-chemotherapy-is-the-treatment-worthwhile
#7
Yun Wang, Zhi-Qiang Wang, Feng-Hua Wang, Yun-Fei Yuan, Bin-Kui Li, Pei-Rong Ding, Gong Chen, Xiao-Jun Wu, Zhen-Hai Lu, Zhi-Zhong Pan, De-Sen Wan, Peng Sun, Shu-Mei Yan, Rui-Hua Xu, Yu-Hong Li
Peri-operative chemotherapy has been proposed to improve the survival of patients with colorectal cancer hepatic metastases (CRCHM). However, the role of the adjuvant chemotherapy post-metastasectomy for CRCHM patients who have undergone pre-operative chemotherapy is still undetermined. We retrospectively analyzed the role of adjuvant chemotherapy post-metastasectomy on relapse-free survival (RFS) and overall survival (OS) in 163 CRCHM patients who received pre-operative chemotherapy using a Kaplan-Meier curve and univariate/multiple Cox model...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28592625/current-clinical-practice-guidelines-for-the-treatment-of-renal-cell-carcinoma-a-systematic-review-and-critical-evaluation
#8
Aristotle Bamias, Bernard Escudier, Cora N Sternberg, Flora Zagouri, Athanasios Dellis, Bob Djavan, Kimon Tzannis, Loukas Kontovinis, Konstantinos Stravodimos, Athanasios Papatsoris, Dionysios Mitropoulos, Charalampos Deliveliotis, Meletios-Athanasios Dimopoulos, Constantine A Constantinides
The landscape of local and systemic therapy of renal cell carcinoma (RCC) is rapidly changing. The increase in the incidental finding of small renal tumors has increased the application of nephron-sparing procedures, while ten novel agents targeting the vascular endothelial growth factor (VEGF) or the mammalian target of rapamycin pathways, or inhibiting the interaction of the programmed death 1 receptor with its ligand, have been approved since 2006 and have dramatically improved the prognosis of metastatic RCC (mRCC)...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28590313/current-management-of-metastatic-renal-cell-carcinoma-evolving-new-therapies
#9
Ravi Kumar, Anil Kapoor
PURPOSE OF REVIEW: Targeted therapies have recently replaced cytokine treatments as the gold standard for management of metastatic renal cell carcinoma (mRCC). Currently approved treatments include the tyrosine kinase inhibitors sunitinib, pazopanib, axitinib, sorafenib, cabozantinib and lenvatinib; the vascular endothelial growth factor (VEGF) inhibitor bevacizumab; the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus; and the immunologic nivolumab. The purpose of this review is to provide an updated analysis of the clinical data supporting the use of these agents in the first-line and second-line setting...
June 5, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28588783/salivary-duct-carcinoma-treated-with-cetuximab-based-targeted-therapy-a-case-report
#10
Kenta Kawahara, Akimitsu Hiraki, Ryoji Yoshida, Hidetaka Arita, Yuichiro Matsuoka, Toshio Yamashita, Kan-Ichi Koga, Masashi Nagata, Akiyuki Hirosue, Daiki Fukuma, Hideki Nakayama
Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes...
June 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28586934/brain-metastases-of-non-small-cell-lung-cancer-prognostic-factors-in-patients-with-surgical-resection
#11
Aida Ramos Antuña, Marco Alvarez Vega, Carmen Rodriguez Sanchez, Vanesa Martin Fernandez
Background and Study Aims Bronchogenic carcinoma is the cancer that most commonly metastasizes to the brain. The standard treatment schedule for these patients is still unclear, although recommendation level 1 class I advocates for surgical resection together with postoperative whole-brain radiotherapy for patients with good Karnofsky performance status (KPS). We performed a study to identify prognostic factors for the long-term survival of patients with brain metastases from non-small cell lung cancer (NSCLC)...
June 6, 2017: Journal of Neurological Surgery. Part A, Central European Neurosurgery
https://www.readbyqxmd.com/read/28577846/surgical-outcome-and-prognostic-stratification-for-pulmonary-metastasis-from-colorectal-cancer
#12
Takehiro Okumura, Narikazu Boku, Tomoyuki Hishida, Yasuhisa Ohde, Yukinori Sakao, Katsuo Yoshiya, Masahiko Higashiyama, Ichinosuke Hyodo, Keita Mori, Haruhiko Kondo
BACKGROUND: This study investigated recent clinical outcomes and prognostic factors of metastasectomy for pulmonary metastasis (PM) from colorectal cancer. METHODS: Data for 785 patients with PM from colorectal cancer who underwent curative resection, including 376 patients treated with postmetastasectomy adjuvant chemotherapy, between 2004 and 2008, were collected from 46 Japanese hospitals. Disease-free and overall survival was analyzed. Potential prognostic factors were assessed...
June 1, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28576747/brief-report-long-term-outcome-of-surgery-or-stereotactic-radiotherapy-for-lung-oligometastases
#13
Joyce E Lodeweges, Theo J Klinkenberg, Jan F Ubbels, Harry J M Groen, Johannes A Langendijk, Joachim Widder
Local treatment for pulmonary oligometastases (one to five lesions) employing metastasectomy or stereotactic ablative radiotherapy (SABR) was investigated in a cohort having received multidisciplinary tumour-board-based treatment decisions. First choice of treatment was surgery, SABR was recommended in case of clinical adverse factors. Propensity-score adjusted and unadjusted overall survival (OS) was the primary endpoint, local control and time-to-failure of a local-only treatment strategy were also analysed...
May 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28573073/late-onset-pulmonary-metastasis-more-than-10-years-after-primary-sigmoid-carcinoma
#14
Anne M Daniels, Jeroen F J Vogelaar
According to current guidelines, follow-up of patients with colorectal cancer is ended after five years. Also, chest X-ray is not part of standard investigation during follow-up. We describe a case of a 74-year-old patient, more than ten years after a sigmoid resection because of carcinoma of the sigmoid. No recurrence was detected during intensive follow-up. However, ten years after resection of the sigmoid adenocarcinoma, complaints of coughing induced further examination with as result the detection of a solitary metastasis in the left lung of the patient...
May 15, 2017: World Journal of Gastrointestinal Pathophysiology
https://www.readbyqxmd.com/read/28553615/a-single-institution-analysis-of-126-patients-treated-with-stereotactic-radiosurgery-for-brain-metastases
#15
Kevin B Harris, Melanie R Corbett, Henry Mascarenhas, Kenneth Stuart Lee, Hyder Arastu, Clinton Leinweber, Andrew W Ju
BACKGROUND: The objective of this study was to report our institutional experience with Gamma Knife(®) Radiosurgery (GKRS) in the treatment of patients with brain metastases. METHODS: Retrospectively collected demographic and clinical data on 126 patients with intracranial metastases were reviewed. The patients in our study underwent GKRS at Vidant Medical Center between 2009 and 2014. Kaplan-Meier curves were used to compare survival based on clinical characteristics for univariate analysis, and a Cox proportional hazards model was used for multivariate analysis...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28534347/recent-perspectives-of-management-of-breast-cancer-metastasis-an-update
#16
Qingzhong Tian, Yun Wang, Hao Guo, Guangwei Xie, Jin Li, Minkang Zhang, Qianjin Zhang, Qingliang Meng
Breast cancer is the leading cause of cancer related deaths in women and one of the most common cancers globally. The major obstacle in the management of breast cancer, especially at advanced stages, is metastasis. Metastasis in the advanced stages of breast cancer could decrease survival to approximately 5 years. The reasons could include lack of targeted receptors or chemotherapeutic agents for the management of advanced-stage breast cancer metastasis. The new emerging avenues for the management of this deadly pathological state include local manipulations like radiofrequency ablation (RFA), microwave thermotherapy, cryosurgery (cryotherapy), chemoembolization, radioembolization, breast surgery, or metastasectomy...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28516157/survival-after-metastasectomy-for-metastatic-urothelial-carcinoma-a-systematic-review-and-meta-analysis
#17
Vaibhav Patel, Ana Collazo Lorduy, Aaron Stern, Omar Fahmy, Rachel Pinotti, Matthew D Galsky, Georgios Gakis
Background: Cisplatin-based combination chemotherapy is standard treatment for metastatic urothelial carcinoma; however, the vast majority of patients experience disease progression. As systemic therapy alone is rarely curative for the treatment of metastatic urothelial cancer, not only are new therapies needed but also refinement of general treatment principles. Herein, we conducted a systematic review and meta-analysis to explore the role of metastasectomy in metastatic urothelial carcinoma. Methods: We conducted a systematic review of the literature regarding local treatment for metastatic urothelial carcinoma...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28493008/role-of-family-history-and-tumor-location-on-prognosis-of-patients-with-colorectal-cancer-and-synchronous-metastases
#18
Colloca Giuseppe, Venturino Antonella
BACKGROUND/AIMS: Family history of colorectal cancer and tumor location along colon-rectum have been reported as prognostic factors. The aim of the current study is to analyze the role of both on overall survival in a series of patients with metastatic colorectal cancer with synchronous metastases. METHODS: A retrospective mono-institutional analysis has been performed on patients, who received chemotherapy from 2004 to 2008. A Cox proportional-hazards regression was used to calculate hazard ratio (HR) for death, after adjustment for other variables (tumor metastasectomy, number of organs involved with metastases, number of anti-neoplastic drugs, age, sex, tumor grade, baseline CEA)...
May 10, 2017: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/28486937/survival-after-initial-lung-metastasectomy-for-metastatic-colorectal-cancer-in-the-modern-chemotherapeutic-era
#19
Shintaro Yokoyama, Masahiro Mitsuoka, Tetsushi Kinugasa, Toshihiro Hashiguchi, Ryoichi Matsumoto, Daigo Murakami, Tatsuya Nishi, Koichi Yoshiyama, Masaki Kashihara, Shinzo Takamori, Yoshito Akagi
BACKGROUND: A clear survival benefit has been reported for lung metastasectomy for colorectal cancer, and several clinicopathological prognostic factors have been proposed in the past. However, clinical advances, such as chemotherapy and radiographic imaging, should have improved patient outcome and may have altered prognosticators. This study aimed to assess patient survival and determine prognostic factors for survival and recurrence in patients who underwent initial lung metastasectomy for colorectal cancer in the modern clinical era...
May 10, 2017: BMC Surgery
https://www.readbyqxmd.com/read/28455994/molecular-profiling-of-colorectal-pulmonary-metastases-and-primary-tumours-implications-for-targeted-treatment
#20
Sing Yu Moorcraft, Thomas Jones, Brian A Walker, George Ladas, E Kalaitzaki, Lina Yuan, Ruwaida Begum, Zakaria Eltahir, Andrew Wotherspoon, Angeles Montero Fernandez, Larissa S Teixeira Mendes, David Gonzalez de Castro, Sanna Hulkki Wilson, Paula Proszek, Ye Mong To, Eliza Hawkes, Amitesh Roy, David Cunningham, Sheela Rao, David Watkins, Naureen Starling, Anne M Bowcock, Ian Chau
This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed paraffin embedded tissue samples were retrospectively collected from patients who underwent ≥ 1 pulmonary metastasectomies for colorectal cancer between 1997-2012. Primary tumour and metastatic samples were analysed using a targeted capture sequencing panel of 46 cancer-associated genes...
April 11, 2017: Oncotarget
keyword
keyword
265
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"